CA2388450C - Tadg-15: an extracellular serine protease overexpressed in carcinomas - Google Patents

Tadg-15: an extracellular serine protease overexpressed in carcinomas Download PDF

Info

Publication number
CA2388450C
CA2388450C CA2388450A CA2388450A CA2388450C CA 2388450 C CA2388450 C CA 2388450C CA 2388450 A CA2388450 A CA 2388450A CA 2388450 A CA2388450 A CA 2388450A CA 2388450 C CA2388450 C CA 2388450C
Authority
CA
Canada
Prior art keywords
tadg
leu
gly
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2388450A
Other languages
English (en)
French (fr)
Other versions
CA2388450A1 (en
Inventor
Timothy J. O'brien
Hirotoshi Tanimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas at Little Rock
Original Assignee
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/421,213 external-priority patent/US7022821B1/en
Application filed by University of Arkansas at Little Rock filed Critical University of Arkansas at Little Rock
Publication of CA2388450A1 publication Critical patent/CA2388450A1/en
Application granted granted Critical
Publication of CA2388450C publication Critical patent/CA2388450C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2388450A 1999-10-20 2000-10-20 Tadg-15: an extracellular serine protease overexpressed in carcinomas Expired - Fee Related CA2388450C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/421,213 1999-10-20
US09/421,213 US7022821B1 (en) 1998-02-20 1999-10-20 Antibody kit for the detection of TADG-15 protein
PCT/US2000/029095 WO2001029056A1 (en) 1999-10-20 2000-10-20 Tadg-15: an extracellular serine protease overexpressed in carcinomas

Publications (2)

Publication Number Publication Date
CA2388450A1 CA2388450A1 (en) 2001-04-26
CA2388450C true CA2388450C (en) 2013-02-12

Family

ID=23669632

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2388450A Expired - Fee Related CA2388450C (en) 1999-10-20 2000-10-20 Tadg-15: an extracellular serine protease overexpressed in carcinomas

Country Status (6)

Country Link
EP (2) EP1226150A4 (enExample)
JP (1) JP2003512036A (enExample)
AU (1) AU774106B2 (enExample)
CA (1) CA2388450C (enExample)
MX (1) MXPA02004046A (enExample)
WO (1) WO2001029056A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795211B2 (en) * 2000-02-22 2010-09-14 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US7572444B2 (en) 2004-12-20 2009-08-11 Amgen Fremont Inc. Binding proteins specific for human matriptase
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
EP2185933B1 (en) 2007-08-07 2015-10-07 Oxford Biotherapeutics Ltd. Matriptase protein and uses thereof
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
AU2011299088B2 (en) 2010-09-09 2015-12-24 Traxxsson, Llc Combination methods of diagnosing cancer in a patient
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
MX2016006486A (es) 2013-11-25 2016-08-05 Oxford Biotherapeutics Ltd Anticuerpos.
US9272027B1 (en) 2014-09-08 2016-03-01 The United States Of America As Represented By The Secretary Of The Air Force Francisella tularensis live vaccine strains and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09149790A (ja) * 1995-09-29 1997-06-10 Suntory Ltd 新規セリンプロテアーゼ
AU6468998A (en) * 1997-03-19 1998-10-12 Board Of Trustees Of The University Of Arkansas, The Compositions and method for the early diagnosis of ovarian cancer
US6203979B1 (en) * 1998-01-16 2001-03-20 Incyte Pharmaceuticals, Inc. Human protease molecules
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
EP1151113A2 (en) * 1999-01-11 2001-11-07 Incyte Pharmaceuticals, Inc. Human peptidases
EP1161266A4 (en) * 1999-03-12 2007-09-19 Univ Georgetown Matriptase, a serine protease and its applications

Also Published As

Publication number Publication date
JP2003512036A (ja) 2003-04-02
EP1887082A3 (en) 2008-06-11
AU1221501A (en) 2001-04-30
MXPA02004046A (es) 2002-10-11
AU774106B2 (en) 2004-06-17
EP1226150A4 (en) 2005-05-25
EP1887082A2 (en) 2008-02-13
EP1226150A1 (en) 2002-07-31
WO2001029056A1 (en) 2001-04-26
CA2388450A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
US6649741B1 (en) TADG-15: an extracellular serine protease overexpressed in carcinomas
US7638277B2 (en) Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
US6294663B1 (en) Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
AU750932B2 (en) TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
US6316213B1 (en) Methods for the early diagnosis of ovarian, breast and lung cancer
CA2402017C (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2001239832B2 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2001239832A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU774106B2 (en) TADG-15: an extracellular serine protease overexpressed in carcinomas
US8216794B2 (en) Extracellular serine protease
US7157084B2 (en) Extracellular serine protease
US6642013B1 (en) Extracellular serine protease
US6875609B2 (en) Methods for the early diagnosis of ovarian cancer
US6870027B2 (en) Methods for the early diagnosis of ovarian cancer
US20020142317A1 (en) Methods for the early diagnosis of ovarian cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171020